Phase III
Boston is getting a new tenant focused on rare diseases. Italian pharma company Chiesi Farmaceutici S.p.A is launching a U.S.-based subsidiary Chiesi Global Rare Diseases with a focus on advancing research and new product development for rare and ultra-rare diseases.
The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.
United Therapeutics announced that its Phase II/III DISTINCT trial failed to meet its primary efficacy endpoint.
No treatments are currently approved for the disease.
Pharma companies from across the globe provide updates on their pipelines and business.
Results from both late-stage trials were announced this week.
In addition to various deal news, AstraZeneca had clinical trial news today as well.
The company hopes to resume the trials following an assessment of data.
“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, Genentech’s chief medical officer and head of Global Product Development.
There were plenty of clinical trial announcements this week. Here’s a look.
PRESS RELEASES